MDACC Study No:2011-0530 ( NCT No: NCT01438554)
Title:A Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma.
Principal Investigator:Vivek Subbiah
Treatment Agent:GSK1120212 ; Pazopanib
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
levels of pazopanib and GSK1120212 (also called trametinib) that can be given
in combination to patients with advanced cancer.

Pazopanib and GSK1120212 are designed to block certain proteins that cause
cancer cells to grow and multiply. This may cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Gastrointestinal; Sarcoma; Solid Tumors; Thyroid
Phase of Study:Phase I
Treatment Agents:GSK1120212
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:National Comprehensive Cancer Network (NCCN)
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Vivek Subbiah
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-794-1226
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults